No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.
Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DFJ, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR.
Mota TM, et al. Among authors: elliott jh.
AIDS. 2017 May 15;31(8):1137-1141. doi: 10.1097/QAD.0000000000001442.
AIDS. 2017.
PMID: 28301423
Free PMC article.